Clinical Inquiry: which patients with metabolic syndrome benefit from metformin?
Stover, L.; Chi, J.; Kelsberg, G.; Safranek, S.
Journal of Family Practice 65(11): 832-834
2016
ISSN/ISBN: 1533-7294 PMID: 28087869 Document Number: 686214
In patients with metabolic syndrome who are in the highest-risk quartile for progression to diabetes (predicted mean 3-year risk, 60%), metformin, 850 mg twice daily, reduces the absolute risk by about 20% over a 3-year period. Metformin doesn't reduce the incidence in patients at lower risk of progression.
Document emailed within 1 workday
Related Documents
Haydardedeoglu, B.; Simsek, E.; Kilicdag, E.B.; Bagis, T. 2009: Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 105(1): 32-35Namak, S.Y.; Kirk, J.K.; Kramer, R. 2013: Clinical inquiry: do patients with type 2 diabetes who aren't taking insulin benefit from self-monitoring blood glucose? Journal of Family Practice 62(1): 39-48
Wu, J.; Zhu, Y.; Jiang, Y.; Cao, Y. 2008: Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 24(7): 392-398
Scheen, A.J.; Paquot, N. 2013: Use of metformin in diabetic patients with cardiac disease: benefit-risk balance Revue Medicale Suisse 9(395): 1527-1533
Jesus, C.át.; Jesus, I.ês.; Agius, M. 2015: A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics Psychiatria Danubina 27(Suppl 1): S489-S491
Tesanović, S.; Radman, M.; Tesanović, D.; Erzen, D.Jurisić.; Hozo, I. 2013: Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention Collegium antropologicum 37(2): 367-371
Bredella, M.A.; McManus, S.; Misra, M. 2013: Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome Clinical Endocrinology 79(2): 199-203
Katayama, S. 2005: Clinical significance of calcium channel blocker in patients with metabolic syndrome Clinical Calcium 15(10): 1657-1662
Lyon, C.; Syfert, J.; Nashelsky, J. 2016: Clinical Inquiry: do corticosteroid injections improve carpal tunnel syndrome symptoms? Journal of Family Practice 65(2): 125-128
Pekhlivanov, B.; Mitkov, M.; Kavŭrdzhikova, S. 2006: Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome Akusherstvo i Ginekologiia 45(6): 29-35
Krivosheev, A.B.; Kuimov, A.D.; Khavin, P.P.; Morozova, A.A. 2009: Non-medicamentous correction of metabolic and functional disorders in the biliary tract of patients with metabolic syndrome Voprosy Kurortologii Fizioterapii i Lechebnoi Fizicheskoi Kultury 2009(4): 23-27
Kiałka, M.; Gałuszka-Bednarczyk, A.; Wajda, A.; Czekańska, P.; Zdzierak, B.; Mrozińska, S.; Janeczko, M.; Milewicz, T. 2017: Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome Przeglad Lekarski 74(4): 144-146
Engstrom, J.; Neher, J.O.; St Anna, L. 2011: Clinical Inquiry. what is the prognosis for patients with chronic urticaria? Journal of Family Practice 60(3): 168a-168b
Joncas, F. 1972: 4 years of clinical experience with metformin in 47 diabetic patients L'union Medicale du Canada 101(1): 65-70
Gaus, O.V.; Akhmedov, V.A. 2015: Dynamic of Clinical, Laboratory and Sonographic Parameters After Successful Litholitic Therapy at Patients with Gallstone Disease in Association with Metabolic Syndrome Eksperimental'naia i Klinicheskaia Gastroenterologiia 2015(7): 18-23
Beck, S.; Ludwig, M.J.; Safranek, S. 2013: Clinical inquiry: how best to treat agitation in patients with irreversible dementia? Journal of Family Practice 62(7): 377-387
Latib, A.; Costopoulos, C.; Naganuma, T.; Colombo, A. 2013: Which patients could benefit the most from bioresorbable vascular scaffold implant: from clinical trials to clinical practice Minerva Cardioangiologica 61(3): 255-262
Koller, M.; Lorenz, W.; Abel, U. 2006: Methodological diversity in clinical research: an evaluation of the overall benefit for patients requires more than the randomised clinical trial MMW Fortschritte der Medizin 148(49-50): 51
Hoeger, K.; Davidson, K.; Kochman, L.; Cherry, T.; Kopin, L.; Guzick, D.S. 2008: The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials Journal of Clinical Endocrinology and Metabolism 93(11): 4299-4306
Rosak, C.; Hövelmann, R.; Martin, J. 2003: Type 2 diabetes -- higher doses of metformin improve metabolic control MMW Fortschritte der Medizin 145(21): 39